Flowchart displaying the steps of the present study. by Jingtian Yang (11966345)

Subjects:

Table5_Effects of exercise modalities on decreased blood pressure in patients with hypertension.docx by Thiago Rozales Ramis (5311217)

GSK343 decreased viability and proliferation in human neuroblastoma PDX cells. by Laura V. Bownes (10276762)

“…GSK343 treatment resulted in significantly decreased viability. (B) COA3 and COA6 (1.5 × 10³) cells were treated with increasing concentrations of GSK343 (0, 5, 15, 25 μM) for 24 hours and proliferation was measured using CellTiter^® assay. …”

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”

SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO. by Pinar Mesci (14053895)

Osr1 heterozygous mice experienced decreased bile acid synthesis in the liver. by Ernest C. Lynch (12769954)

“…Osr1 female mice had significantly increased gene expression of <i>Plin4</i> and <i>Plin5</i>. Data is presented as Mean±SD, N = 5; *p<0.05.…”

Significantly decreased adhesion to host cells by the Δ<i>tad123</i> mutant (A) and time-dependent recovery (B). by Tra-My Duong-Nu (7300970)

Data_Sheet_1_TMPRSS2 gene polymorphism common in East Asians confers decreased COVID-19 susceptibility.docx by Takeshi Sekiya (14194334)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: